Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501Business Wire • 08/16/21
Rocket Pharmaceuticals, Inc. (RCKT) CEO Gaurav Shah on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent ProgressBusiness Wire • 08/09/21
Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business HighlightsBusiness Wire • 08/03/21
Rocket Pharmaceuticals Announces Positive Data From RP-L102, RP-L201 Gene Therapy ProgramsBenzinga • 05/13/21
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell TherapyBusiness Wire • 05/13/21
Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent ProgressBusiness Wire • 05/10/21
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell TherapyBusiness Wire • 04/27/21
Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual MeetingBusiness Wire • 04/14/21
Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-IBusiness Wire • 03/29/21
Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase DeficiencyBusiness Wire • 03/22/21
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-IBusiness Wire • 03/09/21
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational ResultsBusiness Wire • 02/25/21
Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy PipelineBusiness Wire • 01/11/21
Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 12/14/20